An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.

@article{Bedognetti2010AnOR,
  title={An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.},
  author={Davide Bedognetti and Alessandra Rubagotti and Giario Natale Conti and Francesco De Francesca and Ottavio de Cobelli and Luca Canclini and Michele Gallucci and Francesco Aragona and Pasquale Di Tonno and Pietro Cortellini and Giuseppe Martorana and Alberto Lapini and Francesco Boccardo},
  journal={European urology},
  year={2010},
  volume={57 2},
  pages={
          238-45
        }
}
BACKGROUND Bicalutamide monotherapy is a valuable option for prostate cancer (PCa) patients who wish to avoid the consequences of androgen deprivation; however, this treatment induces gynaecomastia and mastalgia in most patients. Tamoxifen is safe and effective in preventing breast events induced by bicalutamide monotherapy without affecting antitumor activity, but possible interference between bicalutamide and tamoxifen remains a matter of concern. To reduce the exposure to tamoxifen, we… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Similar Papers

Loading similar papers…